Citrobacter

Citrobacter can be found in the stool of healthy people. Detecting it does not establish an infection, even when your report draws attention to its abundance. Studies have recovered strains from people with diarrhea and from people without symptoms, sometimes with similar genetic and laboratory characteristics.

Using stool Citrobacter abundance as a health marker remains exploratory. Research has linked it to several conditions, but those associations have not established an individual treatment target or a reliable measure of gut recovery.

What This Organism Is

Citrobacter is a genus of bacteria in the Enterobacteriaceae family, which also includes Escherichia coli and Klebsiella. Citrobacter freundii and Citrobacter koseri are individual species within that genus. They are examples of opportunistic bacteria: they can cause disease when they reach a vulnerable body site or your defenses are impaired.

This stool result reports Citrobacter abundance at the genus level. It combines organisms that can differ in their ability to cause illness and resist antibiotics. A species-specific result provides more detail, but even a species name does not identify the behavior of an individual strain.

Stool describes organisms shed into your bowel contents. An abundance result cannot locate them within the intestine, diagnose small intestinal bacterial overgrowth, or establish that they are causing symptoms.

Carriage Versus Infection

Illness depends on the strain, the body site, and the person carrying it. Abundance alone does not separate harmless carriage from infection, and finding genes associated with disease does not prove that those genes are causing illness.

In an older pediatric study using stool culture, Citrobacter was recovered from 14% of children with diarrhea and 6.5% of healthy controls. Three C. freundii isolates from children with diarrhea produced a heat-stable toxin. The toxin increased intestinal fluid secretion in newborn mice. This supports a possible diarrheal role for some strains, but the mechanism was tested in animals and the study did not establish a diagnostic stool abundance.

Later work on cultured C. freundii from both symptomatic and healthy people found substantial variation in antibiotic resistance and effects on cultured human cells. Some isolates damaged cells in the laboratory, but those properties did not neatly separate isolates from people with diarrhea from those of healthy people.

What Resistance Studies Show

Antibiotic resistance matters when Citrobacter causes an infection, but this abundance result does not determine which antibiotics would work. In one Chinese study, 31.7% of 82 cultured C. freundii isolates were resistant to at least three antibiotic classes. The collection included isolates from both diarrheal outpatients and healthy people. That percentage describes those selected isolates, not your chance of carrying a resistant strain.

Hospital surveillance provides a different kind of evidence. In a study restricted to C. freundii complex organisms producing certain antibiotic-destroying enzymes, 72% of cases were identified from rectal swabs. This shows how often targeted surveillance detects carriage. It does not show that most people with Citrobacter on a stool microbiome report will develop an infection.

A resistance-associated gene also does not always produce measurable resistance. A study in China found the mcr-9 gene in Citrobacter from healthy stool samples and clinical infections. All eight gene-positive isolates remained nonresistant to polymyxin B in susceptibility testing. The researchers demonstrated transfer of the gene between bacteria in a laboratory experiment. These findings concern cultured isolates and their genes, not the amount of Citrobacter in stool.

A population study of Citrobacter bloodstream infections found that they occurred mainly in older people, often with recent healthcare contact. Urinary sources were more common with C. koseri, while abdominal sources were more associated with the C. freundii complex. Those were blood-culture-confirmed infections. They do not establish the risk of invasive disease from an otherwise incidental stool result.

Inflammatory Bowel Disease

An analysis of stool DNA sequencing data found more Citrobacter in groups with Crohn's disease or ulcerative colitis than in healthy controls. C. freundii and C. youngae were enriched in both conditions. Other species differed between the groups, including C. portucalensis and C. werkmanii in ulcerative colitis.

These changes were part of a broader pattern involving Enterobacteriaceae, particularly E. coli and Klebsiella. The analysis does not establish whether Citrobacter contributes to inflammation or expands because of it. It also did not validate the genus-level result as a way to diagnose inflammatory bowel disease or measure your disease activity.

Findings in Premature Infants

In a study of 80 premature infants, stool sequencing found higher Citrobacter relative abundance among infants with feeding intolerance in the subgroup born before 32 weeks. This was an association within a small neonatal population, not evidence that Citrobacter caused the feeding problem.

Another small study linked C. koseri enrichment to necrotizing enterocolitis. This condition causes severe intestinal injury in premature babies. A systematic review also found studies linking Citrobacter to poorer growth in premature infants, although results and growth definitions varied. These findings do not establish what an adult's stool result means.

Cardiovascular and Mortality Associations

A study that recruited 250 adults in Bangladesh found that greater Citrobacter relative abundance in stool DNA sequencing was associated with thicker carotid artery walls. The association was stronger with greater arsenic exposure. This was a cross-sectional comparison of microbial proportions and an ultrasound measurement, so it could not establish cause or show that changing the organism would prevent cardiovascular disease.

A Finnish cohort followed 7,211 adults for nearly 15 years and linked a microbial cluster composed mainly of Enterobacteriaceae to higher mortality. That was a finding about a group of organisms. Adding microbiome information did not improve mortality prediction over conventional risk factors in the study. Neither result establishes stool Citrobacter abundance as a standalone cardiovascular or longevity test.

What a Change Over Time Means

Gut microbial composition changes with stool consistency, medication exposure, diet, and illness. A difference between two samples can therefore have several explanations. A falling Citrobacter result does not by itself demonstrate improved health, and a rising result does not establish a new infection.

When Results Can Be Misleading

• Recent antibiotics: human studies show changes across the gut community that can persist for months, with some effects documented years later. Those studies do not establish that every antibiotic course increases Citrobacter or that its abundance measures recovery.
• Stool consistency and transit: the time stool spends in the bowel is associated with microbial composition. A change between formed and watery stool can complicate comparisons without identifying a particular disease.
• Genus-level reporting: the result combines different species and strains. It does not reveal toxin production or antibiotic susceptibility.
• DNA detection and viability: molecular stool methods can detect DNA from dead as well as living bacteria. Detecting DNA does not establish that the organism is actively causing disease.
• Different measurements: sequencing percentages, targeted DNA abundance measurements, and counts from culture are not interchangeable. A larger percentage can occur because other organisms have decreased.
• Collection and handling: contamination, preservation, storage, and processing can affect a microbial profile. Results from different laboratories should not automatically be treated as a continuous trend.